These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 16306273)

  • 1. Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties.
    Moon C; Krawczyk M; Paik D; Coleman T; Brines M; Juhaszova M; Sollott SJ; Lakatta EG; Talan MI
    J Pharmacol Exp Ther; 2006 Mar; 316(3):999-1005. PubMed ID: 16306273
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A small nonerythropoietic helix B surface peptide based upon erythropoietin structure is cardioprotective against ischemic myocardial damage.
    Ahmet I; Tae HJ; Juhaszova M; Riordon DR; Boheler KR; Sollott SJ; Brines M; Cerami A; Lakatta EG; Talan MI
    Mol Med; 2011; 17(3-4):194-200. PubMed ID: 21170473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury.
    Fiordaliso F; Chimenti S; Staszewsky L; Bai A; Carlo E; Cuccovillo I; Doni M; Mengozzi M; Tonelli R; Ghezzi P; Coleman T; Brines M; Cerami A; Latini R
    Proc Natl Acad Sci U S A; 2005 Feb; 102(6):2046-51. PubMed ID: 15671158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erythropoietin derivate improves left ventricular systolic performance and attenuates left ventricular remodeling in rats with myocardial infarct-induced heart failure.
    Xu K; George I; Klotz S; Hay I; Xydas S; Zhang G; Cerami A; Wang J
    J Cardiovasc Pharmacol; 2010 Nov; 56(5):506-12. PubMed ID: 20881614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats.
    Moon C; Krawczyk M; Ahn D; Ahmet I; Paik D; Lakatta EG; Talan MI
    Proc Natl Acad Sci U S A; 2003 Sep; 100(20):11612-7. PubMed ID: 14500913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbamylated erythropoietin ameliorates cyclosporine nephropathy without stimulating erythropoiesis.
    Abe T; Isaka Y; Imamura R; Kakuta Y; Okumi M; Yazawa K; Ichimaru N; Tsuda H; Nonomura N; Takahara S; Okuyama A
    Cell Transplant; 2012; 21(2-3):571-80. PubMed ID: 22410315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alteration in erythropoietin-induced cardioprotective signaling by postinfarct ventricular remodeling.
    Miki T; Miura T; Yano T; Takahashi A; Sakamoto J; Tanno M; Kobayashi H; Ikeda Y; Nishihara M; Naitoh K; Ohori K; Shimamoto K
    J Pharmacol Exp Ther; 2006 Apr; 317(1):68-75. PubMed ID: 16377761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signaling pathways of cell proliferation are involved in the differential effect of erythropoietin and its carbamylated derivative.
    Chamorro ME; Wenker SD; Vota DM; Vittori DC; Nesse AB
    Biochim Biophys Acta; 2013 Aug; 1833(8):1960-8. PubMed ID: 23602701
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose erythropoietin alters platelet reactivity and bleeding time in rodents in contrast to the neuroprotective variant carbamyl-erythropoietin (CEPO).
    Kirkeby A; Torup L; Bochsen L; Kjalke M; Abel K; Theilgaard-Monch K; Johansson PI; Bjørn SE; Gerwien J; Leist M
    Thromb Haemost; 2008 Apr; 99(4):720-8. PubMed ID: 18392330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Erythropoietin and carbamylated erythropoietin are neuroprotective following spinal cord hemisection in the rat.
    King VR; Averill SA; Hewazy D; Priestley JV; Torup L; Michael-Titus AT
    Eur J Neurosci; 2007 Jul; 26(1):90-100. PubMed ID: 17614942
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effectiveness of a single vs multiple doses of erythropoietin after experimental myocardial infarction in rats.
    Moon C; Krawczyk M; Lakatta EG; Talan MI
    Cardiovasc Drugs Ther; 2006 Aug; 20(4):245-51. PubMed ID: 17019537
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nonerythropoietic derivative of erythropoietin protects against tubulointerstitial injury in a unilateral ureteral obstruction model.
    Kitamura H; Isaka Y; Takabatake Y; Imamura R; Suzuki C; Takahara S; Imai E
    Nephrol Dial Transplant; 2008 May; 23(5):1521-8. PubMed ID: 18194980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietin and its non-erythropoietic derivative: do they ameliorate renal tubulointerstitial injury in ureteral obstruction?
    Srisawat N; Manotham K; Eiam-Ong S; Katavetin P; Praditpornsilpa K; Eiam-Ong S
    Int J Urol; 2008 Oct; 15(11):1011-7. PubMed ID: 18759748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardioprotective effects of erythropoietin in rats subjected to ischemia-reperfusion injury: assessment of infarct size with 99mTc-annexin V.
    Doue T; Ohtsuki K; Ogawa K; Ueda M; Azuma A; Saji H; Strauss HW; Matsubara H
    J Nucl Med; 2008 Oct; 49(10):1694-700. PubMed ID: 18794258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure.
    Westenbrink BD; Ruifrok WP; Voors AA; Tilton RG; van Veldhuisen DJ; Schoemaker RG; van Gilst WH; de Boer RA
    Cardiovasc Res; 2010 Jul; 87(1):30-9. PubMed ID: 20139114
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carbamylated erythropoietin mediates retinal neuroprotection in streptozotocin-induced early-stage diabetic rats.
    Liu X; Zhu B; Zou H; Hu D; Gu Q; Liu K; Xu X
    Graefes Arch Clin Exp Ophthalmol; 2015 Aug; 253(8):1263-72. PubMed ID: 25725621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of erythropoietin on cardiac remodeling after myocardial infarction.
    Nishiya D; Omura T; Shimada K; Matsumoto R; Kusuyama T; Enomoto S; Iwao H; Takeuchi K; Yoshikawa J; Yoshiyama M
    J Pharmacol Sci; 2006 May; 101(1):31-9. PubMed ID: 16717399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Erythropoietin induces neovascularization and improves cardiac function in rats with heart failure after myocardial infarction.
    van der Meer P; Lipsic E; Henning RH; Boddeus K; van der Velden J; Voors AA; van Veldhuisen DJ; van Gilst WH; Schoemaker RG
    J Am Coll Cardiol; 2005 Jul; 46(1):125-33. PubMed ID: 15992646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Carbamylated erythropoietin protects the myocardium from acute ischemia/reperfusion injury through a PI3K/Akt-dependent mechanism.
    Xu X; Cao Z; Cao B; Li J; Guo L; Que L; Ha T; Chen Q; Li C; Li Y
    Surgery; 2009 Sep; 146(3):506-14. PubMed ID: 19715808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-dose erythropoietin improves cardiac function in experimental heart failure without increasing haematocrit.
    Lipsic E; Westenbrink BD; van der Meer P; van der Harst P; Voors AA; van Veldhuisen DJ; Schoemaker RG; van Gilst WH
    Eur J Heart Fail; 2008 Jan; 10(1):22-9. PubMed ID: 18077209
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.